|drug2557||Placebo oral tablet Wiki||0.17|
|D014777||Virus Diseases NIH||0.10|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. The investigators propose to evaluate intravenous administration of convalescent plasma (CP) obtained from COVID19 survivors in COVID19 patients who are in the medium stage. Supportive data exist for use of convalescent plasma in the treatment of COVID19 and other overwhelming viral illnesses. The study team wants to test the hypothesis that treatment with COVID19 CP will demonstrate salutary effects on COVID19 disease severity/duration, with the primary objective to reduce mortality. In addition, a major secondary objective to reduce the requirement for and/or duration of mechanical ventilation. This phase is to test the safety and efficacy of CP therapy.
Description: Change in mortality of high risk COVID 19 disease compared with the control armMeasure: Change in mortality Time: until hospital discharge or a maximum of 60 days whichever comes first
Description: Change in the duration of mechanical ventilation in high risk COVID 19 disease compared with the control armMeasure: Change in requirement for mechanical ventilation Time: until hospital discharge or a maximum of 60 days whichever comes first
Description: Change in the time a participant will remain on the ventilatorMeasure: Change in the duration of mechanical ventilation Time: until hospital discharge or a maximum of 60 days whichever comes first
Description: Incidence of Treatment-Emergent Adverse Events during study periodMeasure: Incidence of Treatment-Emergent Adverse Events Time: Incidence of Treatment-Emergent Adverse Events until hospital discharge or a maximum of 60 days whichever comes first
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports